162 related articles for article (PubMed ID: 35382770)
1. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy.
Crabtree-Ramirez B; Jenkins CA; Shepherd BE; Jayathilake K; Veloso VG; Carriquiry G; Gotuzzo E; Cortes CP; Padgett D; McGowan C; Sierra-Madero J; Koenig S; Pape JW; Sterling TR;
BMC Infect Dis; 2022 Apr; 22(1):341. PubMed ID: 35382770
[TBL] [Abstract][Full Text] [Related]
2. HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease.
Crabtree-Ramírez B; Jenkins C; Jayathilake K; Carriquiry G; Veloso V; Padgett D; Gotuzzo E; Cortes C; Mejia F; McGowan CC; Duda S; Shepherd BE; Sterling TR
Int J Tuberc Lung Dis; 2019 Mar; 23(3):306-314. PubMed ID: 30871661
[TBL] [Abstract][Full Text] [Related]
3. Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries.
Pettit AC; Jenkins CA; Blevins Peratikos M; Yotebieng M; Diero L; Do CD; Ross J; Veloso VG; Hawerlander D; Marcy O; Shepherd BE; Fenner L; Sterling TR;
J Int AIDS Soc; 2019 Dec; 22(12):e25423. PubMed ID: 31814312
[TBL] [Abstract][Full Text] [Related]
4. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
Carriquiry G; Fink V; Koethe JR; Giganti MJ; Jayathilake K; Blevins M; Cahn P; Grinsztejn B; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; McGowan CC; Shepherd BE
J Int AIDS Soc; 2015; 18(1):20016. PubMed ID: 26165322
[TBL] [Abstract][Full Text] [Related]
5. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.
TB:HIV Study writing Group
AIDS; 2017 Jan; 31(3):375-384. PubMed ID: 28081036
[TBL] [Abstract][Full Text] [Related]
6. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
8. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.
Caro-Vega Y; Schultze A; W Efsen AM; Post FA; Panteleev A; Skrahin A; Miro JM; Girardi E; Podlekareva DN; Lundgren JD; Sierra-Madero J; Toibaro J; Andrade-Villanueva J; Tetradov S; Fehr J; Caylà J; Losso MH; Miller RF; Mocroft A; Kirk O; Crabtree-Ramírez B
BMC Infect Dis; 2018 Apr; 18(1):191. PubMed ID: 29685113
[TBL] [Abstract][Full Text] [Related]
9. Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study.
Smiley CL; Rebeiro PF; Cesar C; Belaunzaran-Zamudio PF; Crabtree-Ramirez B; Padgett D; Gotuzzo E; Cortes CP; Pape J; Veloso VG; McGowan CC; Castilho JL;
Lancet HIV; 2021 May; 8(5):e266-e273. PubMed ID: 33891877
[TBL] [Abstract][Full Text] [Related]
10. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Vibhagool A
J Infect; 2006 Mar; 52(3):188-94. PubMed ID: 15992932
[TBL] [Abstract][Full Text] [Related]
11. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis.
Manabe YC; Hermans SM; Lamorde M; Castelnuovo B; Mullins CD; Kuznik A
PLoS One; 2012; 7(6):e39187. PubMed ID: 22723960
[TBL] [Abstract][Full Text] [Related]
13. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
14. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.
Ayele HT; van Mourik MS; Bonten MJ
BMC Infect Dis; 2015 Aug; 15():334. PubMed ID: 26269094
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
16. Integrated therapy for HIV and tuberculosis.
Manosuthi W; Wiboonchutikul S; Sungkanuparph S
AIDS Res Ther; 2016; 13():22. PubMed ID: 27182275
[TBL] [Abstract][Full Text] [Related]
17. Six-month therapy for abdominal tuberculosis.
Jullien S; Jain S; Ryan H; Ahuja V
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
[TBL] [Abstract][Full Text] [Related]
18. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
